ESMO Asia 2025 | Updates in biomarker-based approach in hepatobiliary & pancreatic cancers

Okay, so that is the educational talk. Yeah, so for long story short, it’s HCC. There is no clear biomarker right now at this moment. So we can select the currently approved therapeutic options per clinical situation of each patient with the shared decision making. And currently, it’s a GPC-3-based immunotherapy and FGFR-4 inhibitors investigated for HCC patients. If those therapies are proven to be effective, I believe that there will be the prescription medicines, the biomarker, real biomarker-based therapy could be done in HCC. Impact on cancer, although we have the PARP inhibitor for germline BRCA one or two mutated tumors after the use of the first line. The platinum-based therapy is approved right now, but those patient populations are very small, particularly in the Asian patient population, so less than 5%. So we need a better marker therapy target, But at this moment, there’s no approved drug for pancreatic cancer as a targeted therapy. Currently, KRAS inhibitors and PRMT5 inhibitors are being developed for KRAS mutated pancreatic cancer and the MTOR loss pancreatic cancer. If the dose, we are expecting the success of those drugs in the upcoming phase 3 trials. And for BTC, BTC is a real disease. We could treat the patients based on the biomarker-driven strategies. Currently, in the second-line setting, we have the FGFR inhibitor, IDH1 inhibitor, and the HER2-targeted therapy. It’s currently approved, and because of that, unlike the HCC and pancreatic cancer, molecular profiling, NGS, is strongly recommended if the patients are diagnosed as locally advanced or metastatic disease at the very first time. Currently, all those therapies are now under investigation for the first-line setting to improve the clinical outcomes for the patients with actionable targets. Yeah, that’s all.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.